← 返回

外泌体相关长链非编码 RNA 风险模型可预测乳腺癌患者的生存结局

英文原题:An exosome-related long non-coding RNAs risk model could predict survival outcomes in patients with breast cancer.

查看英文原题

An exosome-related long non-coding RNAs risk model could predict survival outcomes in patients with breast cancer.

PubMed 2022/12/24(内容时间) Sci Rep Q1 · IF 4.9(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

乳腺癌(BC)是全球女性最常见的恶性肿瘤之一。越来越多证据表明,长链非编码 RNA(lncRNA)可能影响 BC 进展。外泌体是一类小型膜性囊泡,据报道可通过转运蛋白质、mRNA、lncRNA 及其他小分子促进肿瘤进展。

然而,外泌体相关 lncRNA 与恶性肿瘤微环境之间的相互作用尚不清楚。因此,本研究分析外泌体相关 lncRNA 与 BC 微环境的关系。研究者从 ExoBCD 数据库提取 121 个外泌体相关基因,以 Pearson 分析筛选外泌体相关 lncRNA;再根据其与 BC 预后的相关性,确定 15 个差异表达 lncRNA。依据从癌症基因组图谱(TCGA)提取的这 15 个 lncRNA 表达总和及回归系数,采用 Cox 回归建立外泌体相关 lncRNA 特征模型。根据训练集风险评分中位数,将训练集和验证集患者划分为低风险组和高风险组。随后构建 lncRNA-mRNA 共表达网络,使用 R 包 clusterProfiler 比较不同风险组富集通路;采用 ESTIMATE 方法和 ssGSEA 数据库分析 ESTIMATE 评分及免疫细胞浸润,并进一步比较免疫检查点相关基因表达、微卫星不稳定性及免疫表型评分。

结果显示不同风险组预后不同,高风险组生存率较低。组间差异表达基因富集于生物学过程和免疫反应通路。高风险 BC 患者 ESTIMATE 评分较低。训练和验证队列均显示,风险评分降低时,活化树突状细胞、B 细胞、CD8⁺ T 细胞、未成熟树突状细胞、树突状细胞、中性粒细胞、巨噬细胞、NK 细胞、浆细胞样树突状细胞、滤泡辅助性 T 细胞、辅助性 T 细胞、TIL 和 Treg 浸润水平明显升高;部分免疫特征也随风险评分降低而显著活化。最终,外泌体相关 lncRNA 风险模型被证明可准确预测 BC 患者免疫治疗应答。研究提示该模型与 BC 患者预后及免疫细胞浸润密切相关,有望助力改善 BC 免疫治疗。

展开英文摘要原文

Breast cancer (BC) is one of the most frequent malignancies among women worldwide. Accumulating evidence indicates that long non-coding RNA (lncRNA) may affect BC progression. Exosomes, a class of small membrane vesicles, have been reported to promote tumor progression through transporting proteins, mRNAs, lncRNAs and some other small molecules.

However, the interaction between exosome-related lncRNAs and the microenvironment of malignancies is unclear. Hence, we proceeded to investigate the relationship between exosome-related lncRNAs and BC microenvironment. 121 exosome-associated genes were extracted from ExoBCD database. Then, the Pearson analysis was used to screened out the exosome-related lncRNAs. After that, 15 exosome-related differentially expressed lncRNAs were identified by the correlation with BC prognosis. According to the sum of the expression of these 15 lncRNAs, extracted from The Cancer Genome Atlas, and the regression coefficients, an exosome-related lncRNAs signature was developed by using Cox regression analysis. With the median risk score of the training set, the patients in training and validation sets were separated to low-risk group and high-risk group. Subsequently, the lncRNA-mRNA co-expression network was constructed. The distinct enrichment pathways were compared among the different risk groups by using the R package clusterProfiler. The ESTIMATE method and ssGESA database were adopted to study the ESTIMATE Score and immune cell infiltration.

Eventually, the expression of immune checkpoint associated genes, microsatellite instable and the immunophenoscore were further analyzed between different risk groups. Different risk groups exhibited different prognosis, with lower survival rate in the high-risk group. The differentially expressed genes between the different risk groups were enriched in biological processes pathways as well as immune responses. BC patients in high-risk group were identified with lower scores of ESTIMATE scores.

Subsequently, we noticed that the infiltrating levels of aDCs, B cells, CD8+ T cells, iDCs, DCs, Neutrophils, macrophages, NK cells, pDCs, Tfh, T helper cells, TIL and Tregs were obvious elevated with the decreased risk score in training and validation cohorts. And some immune signatures were significantly activated with the decreased risk score in both cohorts.

Eventually, the exosome-associated lncRNAs risk model was demonstrated to accurately predict immunotherapy response in patients with BC. The results of our study suggest that exosome-related lncRNAs risk model has close relationship with prognosis and immune cells infiltration in BC patients.

These findings could make a great contribution to improving BC immunotherapy.

论文信息

作者
Qiu P、Guo Q、Lin J、Pan K、Chen J、Ding M
第一作者单位
Department of Breast and Thyroid Surgery, The Second Affiliated Hospital of Fujian Medical University, No.950 Donghai Street, Quanzhou, China.China
通讯作者单位
Department of Breast and Thyroid Surgery, The Second Affiliated Hospital of Fujian Medical University, No.950 Donghai Street, Quanzhou, China. dmj13313831340@163.com.China
期刊
Scientific reports2022 Dec 24
原文标识
PubMed 36566321 · DOI 10.1038/s41598-022-26894-5